ACU Stock Surges on Q2 Earnings Beat Driven by MyMedic Acquisition and Margin Recovery

• Acme United exceeded Q2 2026 estimates with an EPS of $1.22 and revenue of $62.7 million, driven by the MyMedic acquisition and organic growth.
• Management anticipates continued margin expansion as tariff-related costs diminish and lower-cost inventory replaces higher-tariff stock.
• The stock surged nearly 18% following the release, reflecting investor confidence in the company's turnaround strategy.
• Key risks include elevated SG&A expenses at 32% of sales and uneven geographic performance, with Canada currently lagging.

Acme United Corporation (ACU) delivered robust second-quarter 2026 financial results, significantly outperforming analyst expectations across key metrics. Earnings per share (EPS) reached $1.22, surpassing the consensus estimate of $0.81, while revenue climbed to $62.7 million against forecasts of $58.1 million. The company's stock responded positively to the news, surging approximately 17.5% to near its 52-week high of $51.88.

The earnings beat was largely attributed to the recent acquisition of MyMedic, which contributed to a 16% year-over-year increase in sales . On an organic basis, excluding the impact of acquisitions, sales grew by 8%. This dual driver of acquisition-led and organic growth highlights the company's expanding market presence and operational momentum .

Profitability metrics strengthened considerably across the board, with EBITDA reaching $8.8 million, marking a 137% increase year-over-year . The EBITDA margin improved to 14.03%, indicating enhanced operational efficiency . Gross margins also expanded to 42.6%, up from 41.0% in the prior year period, reflecting improved pricing power and cost efficiencies .

How is the MyMedic Acquisition Influencing Growth?

The integration of MyMedic is progressing well, with strategic plans to expand the brand beyond direct-to-consumer channels into mass retail markets . CEO Johnsen highlighted that the company is actively integrating MyMedic, with a specific focus on expanding the product line beyond its current direct-to-consumer model . This strategic shift is expected to unlock new revenue streams and enhance brand visibility in broader retail environments .

The acquisition has been a primary catalyst for the company's recent financial performance, contributing significantly to the 16% year-over-year sales increase . Management anticipates that the continued integration of MyMedic will support long-term growth and profitability . The expansion into mass retail channels represents a key growth vector for the company, diversifying its revenue sources and reducing reliance on direct-to-consumer sales .

What is Driving Margin Recovery and Forward Outlook?

Management, led by CEO Johnsen, provided a constructive outlook for the remainder of the year, expressing confidence in continued margin recovery . They anticipate that margin recovery will be supported by easing tariff pressures as the company transitions from higher-tariff inventory to lower-cost stock . This strategic inventory management is expected to mitigate the impact of ongoing tariff pressures and improve overall profitability .

The company expects strong fourth-quarter profitability driven by seasonal demand trends . This outlook is predicated on the successful execution of the inventory transition strategy and the continued integration of MyMedic . Management's confidence in the fourth quarter reflects a positive assessment of the company's operational trajectory and market conditions .

What Are the Key Risks Facing Acme United?

Despite the positive results, investors should note several risks that could impact future performance. Selling, General, and Administrative (SG&A) expenses remain elevated at 32% of sales, partly due to integration costs . These elevated expenses could pressure net income if not managed effectively in the coming quarters .

Other headwinds include potential tariff and freight cost fluctuations, currency volatility, and uneven geographic performance . The Canadian market is currently lagging behind other regions, which could dampen overall growth . Investors should monitor these risks closely, as they could impact the company's ability to sustain its recent financial momentum .

The company's weighted average shares outstanding increased slightly, with basic shares at 3.82 million and diluted shares at 4.141 million . No dividends were paid during the period, indicating a focus on reinvestment and growth rather than shareholder returns . This capital allocation strategy aligns with the company's aggressive expansion and integration efforts .

Acme United's strong Q2 2026 performance underscores its ability to drive profitability through operational efficiencies and strategic acquisitions . The successful integration of MyMedic and the easing of tariff pressures are key factors supporting the company's positive outlook . However, the presence of elevated SG&A expenses and geographic performance disparities highlights the need for continued operational discipline .